From Libre Pathology
(Redirected from INI1)
Jump to: navigation, search
Immunostain in short

INI1-ve in AT/RT.
Abbreviation SMARCB1, BAF47
Normal staining pattern nuclear staining
Positive any healthy tissue
Negative AT/RT, renal rhabdoid tumour, extrarenal malignant rhabdoid tumour, atypical teratoid/rhabdoid tumour, epithelioid sarcoma

SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily B, member 1, commonly abbreviated SMARCB1, is a diagnostic immunostain, because nuclear staining is lost in some specific types of cancer shown below.

It is also known as INI1, INI-1 and BAF47.


See also


  1. Hornick, Jason (2009). "Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma". American Journal of Surgical Pathology.
  2. Jackson EM, Sievert AJ, Gai X et al. (March 2009). "Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors". Clin. Cancer Res. 15 (6): 1923–30.
  3. Bishop, JA.; Antonescu, CR.; Westra, WH. (Sep 2014). "SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract.". Am J Surg Pathol 38 (9): 1282-9. doi:10.1097/PAS.0000000000000285. PMID 25007146.
  4. Hasselblatt, M.; Isken, S.; Linge, A.; Eikmeier, K.; Jeibmann, A.; Oyen, F.; Nagel, I.; Richter, J. et al. (Feb 2013). "High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors.". Genes Chromosomes Cancer 52 (2): 185-90. doi:10.1002/gcc.22018. PMID 23074045.
  5. Mularz, K.; Harazin-Lechowska, A.; Ambicka, A.; Kruczak, A.; Rozmus-Piętoń, M.; Marchińska-Osika, U.; Swiątkiewicz, I.; Król, M. et al. (Nov 2012). "Specificity and sensitivity of INI-1 labeling in epithelioid sarcoma. Loss of INI1 expression as a frequent immunohistochemical event in synovial sarcoma.". Pol J Pathol 63 (3): 179-83. PMID 23161234.